
Neurogene Inc (NGNE) Stock Forecast & Price Target
Neurogene Inc (NGNE) Analyst Ratings
Bulls say
Neurogene is progressing well with their EXACT technology and potential Biologics License Application for NGN-401 in Rett syndrome. Their recent funding from a follow-on offering has boosted their cash position to support planned commercial-readiness activities. The Phase 1/2 data for NGN-401 remains strong and supports the use of their technology in other indications and programs. Risks include delays in clinical trials and failure to generate favorable data.
Bears say
Neurogene is currently focused on developing a portfolio of products targeting rare neurological diseases using their proprietary transgene regulation technology EXACT and a conventional gene therapy development candidate. With a recent financing of $135M, the company has extended its cash runway into 2029 and has initiated a PPQ campaign set to be completed by the end of 2026. However, with the company's valuation still trading on a value basis compared to its sensitivity to data catalysts and facing competition from other biotech companies like Taysha in the market, there is a risk that Neurogene may not be able to significantly narrow the valuation gap in the near future.
This aggregate rating is based on analysts' research of Neurogene Inc and is not a guaranteed prediction by Public.com or investment advice.
Neurogene Inc (NGNE) Analyst Forecast & Price Prediction
Start investing in Neurogene Inc (NGNE)
Order type
Buy in
Order amount
Est. shares
0 shares